NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Consortium (MMRC) today announced that it has opened six new clinical trials in 2014, and is on track to open more multiple myeloma clinical trials during 2014 than any other year since the Consortium was founded in 2004. These six new trials represent some of the most promising and brand new treatments in development today.
“Together, with our committed and world-class partners, we have opened six incredibly exciting new trials for multiple myeloma patients who are running out of treatment options,” said Fiona An, M.D., Senior Vice President of Clinical Research for the MMRF and MMRC. “There is such a robust pipeline of promising agents – from monoclonal antibodies to first in class novel therapy to all oral regimens –we are confident that they will prove to have a significant impact for many of our patients.”
Help employers find you! Check out all the jobs and post your resume.
“Together, with our committed and world-class partners, we have opened six incredibly exciting new trials for multiple myeloma patients who are running out of treatment options,” said Fiona An, M.D., Senior Vice President of Clinical Research for the MMRF and MMRC. “There is such a robust pipeline of promising agents – from monoclonal antibodies to first in class novel therapy to all oral regimens –we are confident that they will prove to have a significant impact for many of our patients.”
Help employers find you! Check out all the jobs and post your resume.
